drugset / Trial / NCT01080638
Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.
Phase 4
Terminated
150 enrolled
Seoul National University Hospital
Seoul National University Bundang Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.
Timeline
- Start
- 2009-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Outcome
Outcome not reported
Stopped: “The study was terminated early due to a shortage of research and analytical personnel, which prevented the completion of the study as planned”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abciximab | Monoclonal antibody | 0.125 ug/kg | Other |
| Subject | Abciximab | Monoclonal antibody | 0.25 mg/kg | Other |